Therefore, we will not discuss the clinical efficacy of both approved (fenofibrate, bezafibrate, gemfibrozil) and investigational PPARα agonists (LY518674, ZYH7, GW590735, K-111) in dyslipidemia. This evidence concerns the gene PPARA and metabolic syndrome.